These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24094881)

  • 1. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?
    Emsley R; Fleischhacker WW
    Schizophr Res; 2013 Nov; 150(2-3):427-33. PubMed ID: 24094881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.
    Emsley R; Nuamah I; Hough D; Gopal S
    Schizophr Res; 2012 Jun; 138(1):29-34. PubMed ID: 22446143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials.
    Pecenak J
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():49-70. PubMed ID: 17262007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
    Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
    Leucht S; Barnes TR; Kissling W; Engel RR; Correll C; Kane JM
    Am J Psychiatry; 2003 Jul; 160(7):1209-22. PubMed ID: 12832232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia.
    Storosum JG; van Zwieten BJ; Wohlfarth T; de Haan L; Khan A; van den Brink W
    Arch Gen Psychiatry; 2003 Apr; 60(4):365-8. PubMed ID: 12695313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of placebos in clinical trials for acute schizophrenia.
    Addington D
    Can J Psychiatry; 1995 May; 40(4):171-6. PubMed ID: 7621385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia.
    Potkin S; Agid O; Siu C; Watsky E; Vanderburg D; Remington G
    Schizophr Res; 2011 Nov; 132(2-3):108-13. PubMed ID: 21873032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise.
    Lawrence RE; Appelbaum PS; Lieberman JA
    Schizophr Res; 2021 Mar; 229():122-131. PubMed ID: 33234427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.
    Tani H; Takasu S; Uchida H; Suzuki T; Mimura M; Takeuchi H
    Neuropsychopharmacology; 2020 Apr; 45(5):887-901. PubMed ID: 31770770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia.
    Emsley R; Fleischhacker WW; Galderisi S; Halpern LJ; McEvoy JP; Schooler NR
    BMJ; 2016 Sep; 354():i4728. PubMed ID: 27613560
    [No Abstract]   [Full Text] [Related]  

  • 17. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia.
    Isaac M; Koch A
    Eur Neuropsychopharmacol; 2010 Mar; 20(3):139-45. PubMed ID: 20053539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
    Chen AT; Chibnall JT; Nasrallah HA
    Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.